MedTrace Logo

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

NCT03591887 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2023-06-08

No results posted yet for this study

Summary

This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.

The study consists of 52-week Core study and two optional 52-week periods, Extension and Prolongation of Extension.

The Core study consists of three periods: Induction (placebo-controlled, Week 0-12), Optimization (Week 12-24), and Individualization (Week 24-52).

Conditions

Interventions

BIOLOGICAL

ABY-035

ABY-035 solution for injection

BIOLOGICAL

Placebo

Placebo to ABY-035 solution for injection

Sponsors & Collaborators

  • TFS Trial Form Support

    collaborator INDUSTRY

  • Affibody

    lead INDUSTRY

Principal Investigators

  • Sascha Gerdes, Dr. med · Klinik für Dermatologie, Venerologie und Allergologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2019-03-27
Completion
2021-12-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03591887 on ClinicalTrials.gov